Literature DB >> 18047478

The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.

Sunniva Nyberg Karlsen1, Olav Spigset, Lars Slørdal.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a known neurotoxin in animals. This review discusses the history, pattern of use, pharmacology, acute and long-term effects of MDMA. Emphasis is given to the concern that MDMA may induce long-term cognitive and psychiatric effects. MDMA is an illegal substance, and investigations of the effects of exposure in human beings have limitations and weaknesses. There are numerous studies suggesting a correlation between MDMA exposure and psychopathology, and that the psychotropic effects may be long-lasting or permanent. However, it is not possible to conclude that there is a causal relationship between exposure and the increased psychopathology observed in MDMA users. Longitudinal studies are needed to assess whether MDMA causes persistent cognitive impairment and/or psychiatric symptoms in human beings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047478     DOI: 10.1111/j.1742-7843.2007.00159.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  14 in total

1.  Ecstasy use and suicidal behavior among adolescents: findings from a national survey.

Authors:  Jueun Kim; Bin Fan; Xinhua Liu; Nancy Kerner; Ping Wu
Journal:  Suicide Life Threat Behav       Date:  2011-06-01

2.  Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats.

Authors:  Erica Y Shen; Syed F Ali; Jerrold S Meyer
Journal:  Neuropharmacology       Date:  2011-07-13       Impact factor: 5.250

3.  The acute toxic and neurotoxic effects of 3,4-methylenedioxymethamphetamine are more pronounced in adolescent than adult mice.

Authors:  Neha Milind Chitre; Monique Simone Bagwell; Kevin Sean Murnane
Journal:  Behav Brain Res       Date:  2019-12-03       Impact factor: 3.332

4.  Human Ecstasy use is associated with increased cortical excitability: an fMRI study.

Authors:  Amy L Bauernfeind; Mary S Dietrich; Jennifer U Blackford; Evonne J Charboneau; James G Lillevig; Christopher J Cannistraci; Neil D Woodward; Aize Cao; Tristan Watkins; Christina R Di Iorio; Carissa Cascio; Ronald M Salomon; Ronald L Cowan
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

5.  Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Authors:  Berker Duman; Nilay Sedes; Bora Baskak
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

6.  Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.

Authors:  Norbert Gyongyosi; Brigitta Balogh; Zita Katai; Eszter Molnar; Rudolf Laufer; Kornelia Tekes; Gyorgy Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2010-01-06       Impact factor: 3.575

7.  THC Prevents MDMA Neurotoxicity in Mice.

Authors:  Clara Touriño; Andreas Zimmer; Olga Valverde
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

8.  Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum.

Authors:  Karl B Scheidweiler; Bruce Ladenheim; Jean Lud Cadet; Marilyn A Huestis
Journal:  Neurotox Res       Date:  2009-10-23       Impact factor: 3.911

Review 9.  Serotonergic drugs and valvular heart disease.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Expert Opin Drug Saf       Date:  2009-05       Impact factor: 4.250

Review 10.  The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.

Authors:  Thomas Steinkellner; Michael Freissmuth; Harald H Sitte; Therese Montgomery
Journal:  Biol Chem       Date:  2011-01       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.